Overview

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
Phase:
Phase 4
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.